The administration of growth hormone treatment declined in both groups when compared to the earlier measurement cluster, but not significantly (INC 52.1 to 50.0%, CKD 30.6 to 27.5%, both p > 0.05, Table 2). Here, GH1 is linked to chronic kidney disease.